Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adlarity
- Development stage
- Unknown
- Lead developer
- Corium
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
Adlarity is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor, developed by Corium using its proprietary Corplex technology. It is indicated for the treatment of mild, moderate, and severe dementia associated with Alzheimer's disease. Unlike the traditional oral formulation (Aricept), which requires daily dosing, Adlarity is a once-weekly patch designed to provide continuous delivery of donepezil through the skin, bypassing the gastrointestinal tract and potentially reducing the incidence of GI-related adverse effects. The FDA approved Adlarity in March 2022 based on bioequivalence studies comparing it to oral donepezil.
- Brand names
- Adlarity
- Other names
- Donepezil Transdermal SystemDonepezil TDS
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on Adlarity.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adlarity.